| Features: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Berbamine — berbamine is a natural bisbenzylisoquinoline alkaloid with pleiotropic anticancer signaling activity. It is best classified as a plant-derived small-molecule natural product and investigational anticancer lead rather than an approved oncology drug. Standard abbreviation: BBM. It is chiefly isolated from Berberis species, especially Berberis amurensis, and has also been reported in other alkaloid-containing medicinal plants. The strongest mechanistic signal in cancer appears to be inhibition of CaMKIIγ-centered survival signaling, with downstream effects on c-Myc, STAT3, β-catenin, PI3K/Akt-related survival programs, apoptosis, and in some models ROS-linked stress responses. Clinical oncology translation remains limited; most evidence is preclinical, and formulation constraints have been noted because native berbamine has limited tumor-site exposure and short plasma persistence in vivo. Primary mechanisms (ranked):
Bioavailability / PK relevance: Native berbamine appears PK-limited for systemic oncology use. Multiple papers describe short plasma half-life or poor tumor-site exposure as a practical limitation, which is one reason nanoparticle and derivative strategies have been pursued. I did not find a robust modern human PK package for parent berbamine suitable for quantitative clinical extrapolation; stronger PK data were easier to find for derivatives than for the native compound. In-vitro vs systemic exposure relevance: Many mechanistic cancer studies use micromolar in-vitro concentrations, often around 5–20 μM and sometimes higher. That makes direct translation to achievable free systemic exposure uncertain for native berbamine. Mechanistic direction is plausible, but potency-to-exposure matching remains a major translational bottleneck unless formulation or structural optimization is used. Clinical evidence status: Preclinical for cancer. Evidence includes cell culture and xenograft studies across leukemia and several solid tumors, plus medicinal-chemistry optimization work on derivatives. I did not find established randomized oncology trials or standard clinical deployment for cancer treatment. Berbamine is a bisbenzylisoquinoline alkaloid, meaning it is composed of two benzylisoquinoline moieties. Its unique structure distinguishes it from many other natural alkaloids Berbamine is most often isolated from the plant Berberis, commonly known as barberry. Various species within this genus have been used in traditional Chinese medicine and other herbal traditions. plants in genera like Stephania have also been reported to contain bisbenzylisoquinoline alkaloids like berbamine. These plants are used in various parts of Asia both for their stimulant effects and other medicinal purposes.Oxidative Stress: Berbamine can increase the production of reactive oxygen species within cancer cells. Elevated ROS levels may push cancer cells beyond their threshold of tolerance, leading to oxidative stress–induced cell death. This property also ties in with its ability to modulate apoptosis and autophagy. Berbamine is a promising natural compound with multifaceted anticancer properties. Its ability to induce apoptosis, cause cell cycle arrest, modulate key signal transduction pathways (such as JAK/STAT, NF-κB, and PI3K/Akt/mTOR), and affect autophagy, makes it a candidate for further investigation in various cancer models. A calcium channel blocker. Mechanistic relevance in cancer
P: 0–30 min |
| Source: |
| Type: |
| Tumor cell invasion is a critical process in cancer progression and metastasis, where cancer cells spread from the primary tumor to surrounding tissues and distant organs. This process involves several key steps and mechanisms: 1.Epithelial-Mesenchymal Transition (EMT): Many tumors originate from epithelial cells, which are typically organized in layers. During EMT, these cells lose their epithelial characteristics (such as cell-cell adhesion) and gain mesenchymal traits (such as increased motility). This transition is crucial for invasion. 2.Degradation of Extracellular Matrix (ECM): Tumor cells secrete enzymes, such as matrix metalloproteinases (MMPs), that degrade the ECM, allowing cancer cells to invade surrounding tissues. This degradation facilitates the movement of cancer cells through the tissue. 3.Cell Migration: Once the ECM is degraded, cancer cells can migrate. They often use various mechanisms, including amoeboid movement and mesenchymal migration, to move through the tissue. This migration is influenced by various signaling pathways and the tumor microenvironment. 4.Angiogenesis: As tumors grow, they require a blood supply to provide nutrients and oxygen. Tumor cells can stimulate the formation of new blood vessels (angiogenesis) through the release of growth factors like vascular endothelial growth factor (VEGF). This not only supports tumor growth but also provides a route for cancer cells to enter the bloodstream. 5.Invasion into Blood Vessels (Intravasation): Cancer cells can invade nearby blood vessels, allowing them to enter the circulatory system. This step is crucial for metastasis, as it enables cancer cells to travel to distant sites in the body. 6.Survival in Circulation: Once in the bloodstream, cancer cells must survive the immune response and the shear stress of blood flow. They can form clusters with platelets or other cells to evade detection. 7.Extravasation and Colonization: After traveling through the bloodstream, cancer cells can exit the circulation (extravasation) and invade new tissues. They may then establish secondary tumors (metastases) in distant organs. 8.Tumor Microenvironment: The surrounding microenvironment plays a significant role in tumor invasion. Factors such as immune cells, fibroblasts, and signaling molecules can either promote or inhibit invasion and metastasis. |
| 5555- | BBM, | Berbamine inhibits cell proliferation and invasion by increasing FTO expression in renal cell carcinoma cells |
| - | vitro+vivo, | RCC, | NA |
| 5540- | BBM, | Berbamine Inhibits Cell Proliferation and Migration and Induces Cell Death of Lung Cancer Cells via Regulating c-Maf, PI3K/Akt, and MDM2-P53 Pathways |
| - | vitro+vivo, | NSCLC, | NA |
| 5536- | BBM, | Regulation of Cell-Signaling Pathways by Berbamine in Different Cancers |
| - | Review, | Var, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:40 Target#:324 State#:% Dir#:1
wNotes=0 sortOrder:rid,rpid